الفهرس 
PreeclampsiaOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
Summary The role of low dose aspirin and low molecular weight heparin in prevention of preeclampsia is controversial. The present study aimed to evaluate the role of low molecular weight heparin in the prevention of preeclampsia. The study recruited 160 pregnant women with high risk of developing PE. They were randomly divided into 4 equal groups: group I received low molecular weight heparin, (enoxaparin 4000 I.U. daily subcutaneous injection) only, group II received oral low dose aspirin (75 mg) daily, group III received both low molecular weight heparin 4000 I.U and low dose aspirin (75 mg) daily and group IV didn’t receive any of the previous drugs and was considered as control group. All participants were subjected to detailed history taking, physical examination and routine investigations including complete blood picture, RH typing, fasting blood glucose level, liver function tests, kidney function tests and urine analysis. They were followed up until delivery. The development of PE, pregnancy outcome and pregnancy complications were documented. At the end of the study, PE developed in 4 patients (10.0 %) in group I and in group II. While group III witnessed no cases of PE, group 4 had the maximum rate with 11 cases (27.5 %). These results show the significantly lower PE rate in group III in comparison to other study groups and in groups I and II in comparison to controls. The present study also found that administration of LDA or LMWH or both reduced the frequency of early PE in comparison to